Cryptosporidium infection in patients with primary immunodeficiencies.
BACKGROUND
Cryptosporidium species infection is usually self-limited in immunocompetent populations, but can be severe and life-threatening among immunocompromised individuals, particularly in patients with AIDS and in these patients with primary immunodeficiencies (PIDs).


METHODS
A group of 5 patients with genetically confirmed hyper-IgM syndrome type 1 (XHIM) and one patient with primary CD4 lymphopenia were enrolled in the study. At least 2 stool samples and a bile sample in one patient were examined for Cryptosporidium oocysts by a modified Ziehl-Neelsen technique, by immunofluorescence assay using a commercial kit, as well as by molecular analysis followed by genotyping. Immunological status at the time of PID diagnosis and the complex picture of disease are presented.


RESULTS
Chronic cryptosporidiosis was confirmed in 3 patients with XHIM and in one patient with primary CD4 lymphopenia. Molecular diagnosis showed the presence of C parvum, C hominis, and C meleagridis in analyzed specimens.


CONCLUSIONS
Cryptosporidium infection with serious clinical symptoms observed in patients with hyper-IgM syndrome calls for regular, repeated screening in this group of patients.
Wolska-Kusnierz
Beata
B
Gastroenterology, Hepatology and Immunology Clinic, Children's Memorial Health Institute, Italy. bwolska@interia.pl
Bajer
Anna
A
Caccio
Simone
S
Heropolitanska-Pliszka
Edyta
E
Bernatowska
Ewa
E
Socha
Piotr
P
van Dongen
Jacques
J
Bednarska
Malgorzata
M
Paziewska
Anna
A
Sinski
Edward
E
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D017963:Azithromycin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003457:Cryptosporidiosis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D003458:Cryptosporidium / Q000302:isolation & purification*; D017809:Fatal Outcome; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053306:Hyper-IgM Immunodeficiency Syndrome / Q000150:complications / Q000276:immunology / Q000628:therapy; D016867:Immunocompromised Host; D007136:Immunoglobulins / Q000008:administration & dosage; D007153:Immunologic Deficiency Syndromes / Q000150:complications* / Q000276:immunology / Q000628:therapy; D007223:Infant; D008297:Male; D010303:Paromomycin / Q000008:administration & dosage; D011044:Poland; D012189:Retrospective Studies; D018344:T-Lymphocytopenia, Idiopathic CD4-Positive / Q000150:complications / Q000276:immunology / Q000628:therapy
D000900:Anti-Bacterial Agents; D007136:Immunoglobulins; D010303:Paromomycin; D017963:Azithromycin